A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis.
Atopic dermatitis (AD) increases health care utilization, affects patient quality of life, places a burden on caregivers, decreases patient/parent productivity, and adds to health care costs. Few studies have examined the effect of specific treatment modalities across a variety of AD-related outcomes. This prospective, multicenter, open-label longitudinal study of adult and pediatric patients with moderate to severe AD was conducted to evaluate the effect of a specific therapeutic intervention on AD-related outcomes over a period of 6 months. Surveys collected physician clinical assessments and patient- and caregiver-reported data across the following domains: clinical outcome, health care utilization/costs, quality of life, physical appearance, productivity/absenteeism, and medication compliance. This study is intended to help guide future research efforts on the net costs and benefits of different interventions across a diverse set of domains and in larger populations.
National Jewish Medical and Research Center, Denver, CO, USA.
Mark
M
Boguniewicz
William
W
Abramovits
Amy
A
Paller
Diane L
DL
Whitaker-Worth
Mary
M
Prendergast
J Wang
JW
Cheng
Patrick
P
Wang
Kuo B
KB
Tong
D000287:Administration, Topical; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000191:economics* / Q000473:pathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D008297:Male; D004366:Nonprescription Drugs / Q000191:economics / Q000627:therapeutic use; D009824:Ointments; D010349:Patient Compliance / Q000706:statistics & numerical data; D010352:Patient Dropouts / Q000706:statistics & numerical data; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016559:Tacrolimus / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D004366:Nonprescription Drugs; D009824:Ointments; D016559:Tacrolimus